435 related articles for article (PubMed ID: 29019269)
1. The burden of severe hypoglycemia in type 1 diabetes.
Liu J; Wang R; Ganz ML; Paprocki Y; Schneider D; Weatherall J
Curr Med Res Opin; 2018 Jan; 34(1):171-177. PubMed ID: 29019269
[TBL] [Abstract][Full Text] [Related]
2. The burden of severe hypoglycemia in type 2 diabetes.
Liu J; Wang R; Ganz ML; Paprocki Y; Schneider D; Weatherall J
Curr Med Res Opin; 2018 Jan; 34(1):179-186. PubMed ID: 29017368
[TBL] [Abstract][Full Text] [Related]
3. Association of Cumulative Multimorbidity, Glycemic Control, and Medication Use With Hypoglycemia-Related Emergency Department Visits and Hospitalizations Among Adults With Diabetes.
McCoy RG; Lipska KJ; Van Houten HK; Shah ND
JAMA Netw Open; 2020 Jan; 3(1):e1919099. PubMed ID: 31922562
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States.
Simeone JC; Shah S; Ganz ML; Sullivan S; Koralova A; LeGrand J; Bushman J
J Manag Care Spec Pharm; 2020 Nov; 26(11):1399-1410. PubMed ID: 33119443
[No Abstract] [Full Text] [Related]
5. Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections. Results of the HYPOS-1 study.
Giorda CB; Rossi MC; Ozzello O; Gentile S; Aglialoro A; Chiambretti A; Baccetti F; Gentile FM; Romeo F; Lucisano G; Nicolucci A;
Nutr Metab Cardiovasc Dis; 2017 Mar; 27(3):209-216. PubMed ID: 28017523
[TBL] [Abstract][Full Text] [Related]
6. Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization.
Dalal MR; Kazemi M; Ye F; Xie L
Adv Ther; 2017 Sep; 34(9):2083-2092. PubMed ID: 28779282
[TBL] [Abstract][Full Text] [Related]
7. Economic Impact of Treatment Duration and Persistence with Basal Insulin in Previously Insulin-Naive Users.
Kalirai S; Duan R; Liu D; Reed BL
J Manag Care Spec Pharm; 2017 Mar; 23(3):327-336. PubMed ID: 28230446
[TBL] [Abstract][Full Text] [Related]
8. Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States.
Bajpai S; Wong-Jacobson S; Liu D; Mitchell B; Haynes G; Syring K; Ali AK; Chinthammit C
J Manag Care Spec Pharm; 2021 Mar; 27(3):385-391. PubMed ID: 33645242
[No Abstract] [Full Text] [Related]
9. Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes.
Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ
Clin Interv Aging; 2015; 10():991-1001. PubMed ID: 26124652
[TBL] [Abstract][Full Text] [Related]
10. Impact of a clinical pharmacy program on changes in hemoglobin A1c, diabetes-related hospitalizations, and diabetes-related emergency department visits for patients with diabetes in an underserved population.
Chung N; Rascati K; Lopez D; Jokerst J; Garza A
J Manag Care Spec Pharm; 2014 Sep; 20(9):914-9. PubMed ID: 25166290
[TBL] [Abstract][Full Text] [Related]
11. The Burden of Hypoglycemia in Patients With Insulin-Treated Diabetes Mellitus in China: Analysis of Electronic Medical Records From 4 Tertiary Hospitals.
Yue X; Wu J; Ruan Z; Wolden ML; Li L; Lin Y
Value Health Reg Issues; 2020 May; 21():17-21. PubMed ID: 31634792
[TBL] [Abstract][Full Text] [Related]
12. Insulin dosing and outcomes among commercially insured patients with type 2 diabetes in the United States.
Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ
Clin Ther; 2015 Oct; 37(10):2297-2308.e1. PubMed ID: 26341171
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycemia-related emergency department visits and hypoglycemia-related hospitalizations among new users of antidiabetes treatments.
Moisan J; Breton MC; Villeneuve J; Grégoire JP
Can J Diabetes; 2013 Jun; 37(3):143-9. PubMed ID: 24070836
[TBL] [Abstract][Full Text] [Related]
14. Association between hypoglycemia and inpatient mortality and length of hospital stay in hospitalized, insulin-treated patients.
Brodovicz KG; Mehta V; Zhang Q; Zhao C; Davies MJ; Chen J; Radican L; Engel SS
Curr Med Res Opin; 2013 Feb; 29(2):101-7. PubMed ID: 23198978
[TBL] [Abstract][Full Text] [Related]
15. Severe hypoglycemia rates and associated costs among type 2 diabetics starting basal insulin therapy in the United States.
Ganz ML; Wintfeld NS; Li Q; Lee YC; Gatt E; Huang JC
Curr Med Res Opin; 2014 Oct; 30(10):1991-2000. PubMed ID: 24945720
[TBL] [Abstract][Full Text] [Related]
16. The economic impact of insulin-related hypoglycemia in Denmark: an analysis using the Local Impact of Hypoglycemia Tool.
Hoskins N; Tikkanen CK; Pedersen-Bjergaard U
J Med Econ; 2017 Apr; 20(4):363-370. PubMed ID: 27926814
[TBL] [Abstract][Full Text] [Related]
17. Indonesia Cohort of IO HAT Study to Evaluate Diabetes Management, Control, and Complications in Retrospective and Prospective Periods Among Insulin-Treated Patients with Type 1 and Type 2 Diabetes.
Rudijanto A; Saraswati MR; Yunir E; Kumala P; Puteri HH; Mandang VV
Acta Med Indones; 2018 Jan; 50(1):26-37. PubMed ID: 29686173
[TBL] [Abstract][Full Text] [Related]
18. Hypoglycemia in patients with type 2 diabetes newly initiated on basal insulin in the US in a community setting: impact on treatment discontinuation and hospitalization.
Dalal MR; Kazemi MR; Ye F
Curr Med Res Opin; 2017 Feb; 33(2):209-214. PubMed ID: 27737571
[TBL] [Abstract][Full Text] [Related]
19. Top 10 Facts to Know About Inpatient Glycemic Control.
Horton WB; Subauste JS
Am J Med; 2016 Feb; 129(2):139-42. PubMed ID: 26522798
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
